evipedia.ai
← Back

trans-Resveratrol for Health & Longevity

Evidence Review created on 11/01/2026 using AI4L / Opus 5.5

Also known as: Resveratrol, t-Resveratrol, trans-3,5,4′-trihydroxystilbene, 3,5,4′-trihydroxy-trans-stilbene, SRT501, resVida, Veri-te

Motivation

trans-Resveratrol is the main natural form of resveratrol, a compound that grapes, berries, peanuts, and Japanese knotweed produce to defend themselves against fungi and ultraviolet light. It is sold as a dietary supplement and is widely taken by people pursuing longer, healthier lives, chiefly because it was proposed to switch on the same cellular repair programs that calorie restriction engages.

Interest began with efforts to explain the “French paradox”, a long-debated pattern of heart disease in a wine-drinking population, and grew sharply in the early 2000s when laboratory studies in yeast, worms, and mice examined whether the compound could slow aging. That work drew commercial investment and made resveratrol one of the first molecules marketed specifically for longevity, while researchers continue to debate how it acts and how much of it reaches the body’s tissues.

This review examines the human and animal evidence on trans-resveratrol for health and longevity in health-focused adults: its proposed mechanisms, the benefits and risks reported in clinical trials, interactions with medicines and exercise, dosing practices, and what ongoing studies are testing.

Benefits - Risks - Protocol - Conclusion

This section lists high-level overviews of resveratrol from longevity-focused experts and organizations.

Content was found for all six priority experts; a Chris Kresser interview, RHR: How to Slow Aging and Increase Healthspan, with Dr. David Sinclair, also covers resveratrol but was left out to keep the list at five items.

Grokipedia

Resveratrol

AI-generated, AI-fact-checked encyclopedia entry covering chemistry, absorption and metabolism, cardiovascular, metabolic, neurological and lifespan research, safety, and drug interactions; useful as a broad map, not a primary source.

Examine

Resveratrol

Evidence-graded page summarizing 8 trials and 22 meta-analyses across 27 conditions and goals, with dosage ranges and the note that human lifespan evidence is absent.

ConsumerLab

Resveratrol Supplements Review (From Red Wine, Knotweed, and Other Sources)

Independent product testing of label accuracy and purity with an evidence summary; the free summary rates most promoted uses as limited or contradictory, and full results require membership.

Systematic Reviews

The reviews below cover resveratrol’s main cardiometabolic, exercise-training, and safety questions in adults.

Mechanism of Action

Resveratrol is a phytoalexin (a defense compound plants make under fungal or ultraviolet stress). Three mechanisms are proposed:

  • Sirtuin activation: Sinclair’s laboratory, which later co-founded Sirtris to sell sirtuin activators, reported that resveratrol activates SIRT1 (sirtuin 1, an enzyme that uses NAD+, nicotinamide adenine dinucleotide, a cellular energy carrier, to remove acetyl tags from metabolic and stress-response proteins) (Howitz 2003). Competing work found activation only with a fluorescent test substrate (Kaeberlein 2005; Pacholec 2010, Pfizer scientists), while Sinclair’s group later reported allosteric (shape-changing, off-site) activation requiring specific substrate features (Hubbard 2013).
  • Energy sensing: resveratrol inhibits PDE (phosphodiesterases, enzymes that degrade the messenger molecule cAMP, cyclic adenosine monophosphate), which activates AMPK (AMP-activated protein kinase, the cell’s fuel gauge) and, downstream, SIRT1 (Park 2012).
  • Estrogen receptor binding: it acts as a variable agonist (activator) of the estrogen receptor in cell lines (Gehm 1997).

At least 70% of an oral dose is absorbed, but rapid sulfation and glucuronidation by sulfotransferase and UGT enzymes (which attach sulfate or glucuronic acid for excretion) in gut and liver leave only trace unchanged resveratrol in plasma (Walle 2004). The parent compound’s half-life is 1–3 hours after one dose and 2–5 hours with repeated dosing (Almeida 2009), while metabolites have a half-life of about 9 hours (Walle 2004). It reaches cerebrospinal fluid (Turner 2015), has low selectivity (many off-target actions) (Pacholec 2010), and at 1 g/day inhibits CYP3A4, CYP2D6, and CYP2C9 while inducing CYP1A2 (liver enzymes that break down many drugs) (Chow 2010).

Historical Context & Evolution

Resveratrol was first isolated in Japan in the late 1930s from white hellebore (Veratrum grandiflorum); the root of Japanese knotweed (Reynoutria japonica), its main commercial source today, has a long history in Chinese and Japanese herbal practice. Interest in wine constituents grew after the “French paradox”, low coronary mortality despite high saturated-fat intake, was linked to wine drinking (Renaud 1992), and in 1997 resveratrol showed cancer-preventive activity in cell and mouse models (Jang 1997).

Its use for health optimization began in 2003, when Sinclair’s laboratory reported that it activated sirtuins and extended yeast lifespan by 70% (Howitz 2003), followed by worm and fly lifespan gains (Wood 2004) and better survival in mice on a high-calorie diet (Baur 2006). Sirtris, co-founded by Sinclair, was acquired by GlaxoSmithKline in 2008.

Later findings complicated the picture. An independent laboratory saw no fly lifespan effect and variable worm effects (Bass 2007); mice on standard diets aged better on several measures but did not live longer (Pearson 2008; Miller 2011); direct sirtuin activation was questioned on assay grounds and then defended (Kaeberlein 2005; Hubbard 2013); and a trial of SRT501 (a micronized, or finely milled, high-dose formulation) in multiple myeloma (a bone-marrow cancer) was terminated after kidney failures (Popat 2013; NCT00920556). Human trials since 2011 have produced both positive and null metabolic results (Timmers 2011, co-authored by staff of resVida maker DSM; Poulsen 2013), so the debate has shifted from lifespan to modest, population-specific effects.

Expected Benefits

High 🟩 🟩 🟩

Waist Circumference and Body Mass Index ⚠️ Conflicted

BMI (body mass index, a weight-for-height measure) fell versus placebo in a Tabriz trial (Asghari 2018), waist and BMI fell on resveratrol in an independent Guadalajara trial (Méndez-del Villar 2014), and 28 pooled trials showed small falls in both (Mousavi 2019). An umbrella analysis confirmed BMI and waist reductions but found no overall body-weight effect (Molani-Gol 2024), and a trial of 1.5 g/day in obese men found no change in body composition (Poulsen 2013). Net: a consistent but very small reduction of little practical size for lean, active adults.

Magnitude: Waist circumference 0.79 cm smaller than control (95% CI, the confidence interval within which the true value likely lies: −1.39 to −0.20) and BMI 0.17 kg/m² lower (95% CI −0.32 to −0.03) across 28 trials (Mousavi 2019).

Medium 🟩 🟩

Daily Functioning in Alzheimer’s Disease

In a 52-week RCT (randomized controlled trial) of 119 people with mild-to-moderate Alzheimer’s disease, resveratrol escalated to 1 g twice daily slowed decline on the ADCS-ADL (a validated scale of everyday activities), a secondary outcome (Turner 2015). The trial was too small to reliably detect clinical effects, found no effect on four other clinical scales, and brain volume fell more with resveratrol. As a single trial in a disease population, it does not speak to cognitively healthy adults.

Magnitude: ADCS-ADL scores declined less with resveratrol (63.7 to 57.4) than with placebo (60.5 to 51.3; p = 0.03, p being the probability of such a difference arising by chance); the paper reports each group’s scores but no between-group difference figure (Turner 2015).

Chronic Pain in Postmenopausal Women

A meta-analysis of 10 RCTs in postmenopausal women found lower pain scores with resveratrol than placebo (Wu 2025). Both pain trials came from one research group in Newcastle, Australia (Wong 2017; Thaung Zaw 2020). The same analysis found no effect on cognition, mood, metabolic markers, or menopausal symptoms. As single-group data in postmenopausal women, the finding awaits independent replication and does not extend to men.

Magnitude: Pain VAS (visual analogue scale, a line-marking pain rating) score 7.6 points lower than placebo (95% CI −12.9 to −2.3; Wu 2025).

Quality of Life in Ulcerative Colitis

In mild-to-moderate active ulcerative colitis (a chronic inflammatory bowel disease), 500 mg/day for six weeks raised quality-of-life scores and lowered disease-activity scores versus placebo in a Tehran trial (Samsami-Kor 2015). A meta-analysis of human trials rated the quality-of-life gain as high-certainty (Giang 2022), and a network meta-analysis found higher IBDQ (inflammatory bowel disease questionnaire, a validated quality-of-life scale) scores (Xu 2026). The resveratrol data come from one research group in a disease population and do not extend to healthy adults.

Magnitude: IBDQ score 9.18 points higher than conventional treatment or placebo (95% CI 2.45 to 15.91; Xu 2026).

Low 🟩

Glycemic Control in Type 2 Diabetes ⚠️ Conflicted

Resveratrol lowered HbA1c (three-month blood-sugar average) in trials from India (Bhatt 2012) and Iran (Movahed 2013); an umbrella review found a short-term fall (Zeraattalab-Motlagh 2021). A Cochrane review (Jeyaraman 2020) and an umbrella review of 10 meta-analyses (Ghalichi 2026) found no HbA1c effect. Net: pooled evidence outweighs the positive trials.

Magnitude: HbA1c 1.05 percentage points lower than control in trials under 12 weeks (95% CI −2.09 to −0.02; Zeraattalab-Motlagh 2021); the Cochrane estimate was 0.1 points higher than placebo (95% CI −0.02 to 0.2; Jeyaraman 2020).

Blood Pressure ⚠️ Conflicted

Across 17 RCTs, resveratrol did not lower blood pressure overall; reductions appeared only at 300 mg/day or more and in diabetes (Fogacci 2019). An earlier meta-analysis found systolic reductions at 150 mg/day or more (Liu 2015). Net: no reliable effect outside those subgroups.

Magnitude: Systolic pressure 2.5 mmHg lower than control, not significant (95% CI −5.5 to 0.6; Fogacci 2019); 11.9 mmHg lower at 150 mg/day or more in a subgroup (95% CI −20.99 to −2.81; Liu 2015).

LDL and Total Cholesterol ⚠️ Conflicted

A meta-analysis of 25 RCTs reported lower LDL (low-density lipoprotein, the plaque-linked cholesterol carrier) (Zhou 2022) and, at high certainty, lower total cholesterol in overweight adults (Sun 2026). Another found no change (Sahebkar 2015), nor did nonobese women (Yoshino 2012). Net: no dependable effect in metabolically healthy adults.

Magnitude: LDL lower than control by a standardized mean difference (SMD, the effect expressed in standard-deviation units) of −0.42 (95% CI −0.57 to −0.27; Zhou 2022); total cholesterol 0.19 mmol/L lower in overweight adults (95% CI −0.32 to −0.06; Sun 2026); LDL 0.31 mg/dL lower, not significant (95% CI −9.57 to 8.95; Sahebkar 2015).

Bone Mineral Density ⚠️ Conflicted

Two independent RCTs reported BMD (bone mineral density) gains: postmenopausal women on 75 mg twice daily (Wong 2020) and obese men on 1,000 mg/day (Ornstrup 2014). A meta-analysis of 10 RCTs found no BMD effect (Li 2021). Net: the pooled null outweighs the single trials.

Magnitude: Lumbar spine BMD 0.02 g/cm² lower than placebo, not significant (95% CI −0.05 to 0.01; Li 2021); 0.016 g/cm² higher than placebo after 12 months in postmenopausal women (Wong 2020).

Cognitive Performance in Older Adults ⚠️ Conflicted

Positive RCTs used 200 mg/day for 26 weeks (Witte 2014) and 75 mg twice daily for 12 months in postmenopausal women (Thaung Zaw 2020). A larger replication found no memory benefit (Huhn 2018), as did a meta-analysis (Khorshidi 2021). Net: any effect is small.

Magnitude: Overall cognitive performance improved by a Cohen’s d (standardized effect size; 0.2 is conventionally small) of 0.18 versus placebo (Thaung Zaw 2020); pooled human analyses found no significant effect (Khorshidi 2021).

Muscle Strength With Exercise in Older Adults ⚠️ Conflicted

In adults aged 65–80 on 12 weeks of training, 500 mg/day raised knee-extensor strength while exercise alone did not (Alway 2017); an older-adult systematic review concurred (Yadegar 2024). The evidence is indirect: resveratrol was tested only with exercise. Net: a single-trial signal against pooled training data leaning negative (Martinez-Negrin 2022).

Magnitude: Knee-extensor peak torque rose 8% and power 14% with resveratrol after training, with no increase on placebo; not compared between groups (Alway 2017).

Fatty Liver Disease ⚠️ Conflicted

In NAFLD (non-alcoholic fatty liver disease), 500 mg/day with lifestyle advice lowered ALT (alanine aminotransferase, a liver-injury enzyme) versus placebo (Faghihzadeh 2014). Higher-dose trials found no benefit (Heebøll 2016; Chachay 2014). Net: no reliable liver benefit.

Magnitude: At 1.5 g/day for six months, neither ALT (the primary outcome; p = 0.51) nor liver fat (p = 0.38) differed between resveratrol and placebo; the study abstract reports no between-group effect size (Heebøll 2016).

Kidney Function Markers ⚠️ Conflicted

A meta-analysis of 31 RCTs found lower BUN (blood urea nitrogen, a kidney waste marker) than placebo (Hajhashemy 2025). GFR (glomerular filtration rate, kidney filtering capacity), a validated kidney surrogate, rose only in subgroups without diabetes or with use beyond 8 weeks. Net: no consistent overall GFR benefit.

Magnitude: BUN 1.20 mg/dL lower than placebo (95% CI −1.89 to −0.51); GFR rose only in subgroups, for which the abstract reports no figure (Hajhashemy 2025).

Androgen Excess in Polycystic Ovary Syndrome ⚠️ Conflicted

In PCOS (polycystic ovary syndrome, a hormonal disorder with androgen excess), four pooled RCTs showed lower testosterone, LH (luteinizing hormone, an ovary-stimulating hormone), and DHEAS (an adrenal hormone precursor) (Ali Fadlalmola 2023). Three pooled RCTs found less acne but unchanged testosterone (Larik 2024). Net: small, inconsistent hormonal effects.

Magnitude: Testosterone lower than placebo by an SMD of −0.40 (95% CI −0.71 to −0.10; Ali Fadlalmola 2023); acne scores improved versus placebo (p = 0.008), and the abstract reports no effect figure (Larik 2024).

Periodontal (Gum) Health as an Add-On to Dental Treatment

Added to scaling and root planing (deep dental cleaning), resveratrol capsules, gel, or mouthwash reduced gum-pocket depth in a meta-analysis of three small trials from Iran, Egypt, and Iraq (Su 2026). The evidence is indirect: resveratrol was tested only alongside dental treatment, mostly by topical routes.

Magnitude: Probing pocket depth (gum-pocket depth measured with a dental probe) 0.50 mm smaller than with root planing alone (95% CI −0.72 to −0.28; 3 trials; Su 2026).

Fertilization Rate in Assisted Reproduction ⭕️ Not Central to Health & Longevity

In women undergoing IVF (in vitro fertilization), a meta-analysis of 7 studies found higher fertilization rates with resveratrol but unchanged pregnancy and live birth rates (Lemos 2026). It bears on reproductive outcomes only. The evidence is indirect: some studies added vitamins, and the pool mixed randomized and observational designs.

Magnitude: Fertilization rate higher by a mean difference of 2.89 than without resveratrol (95% CI 1.68 to 4.10); pregnancy and live birth rates did not differ (Lemos 2026).

Speculative 🟨

Lifespan Extension ⚠️ Conflicted

Lifespan gains appeared in yeast (Howitz 2003), worms (Wood 2004), and high-calorie-fed mice (Baur 2006), not standard-diet mice (Miller 2011); dietary resveratrol did not predict human mortality (Semba 2014). Net: unsupported in mammals.

Inflammatory Markers ⚠️ Conflicted

CRP (C-reactive protein, an inflammation marker) and TNF-α (tumor necrosis factor-alpha, an inflammatory signal) fell in one meta-analysis (Koushki 2018); CRP did not in another (Sahebkar 2015). Neither is a validated surrogate. Net: inconsistent shifts.

Endothelial Function

A meta-analysis of 17 trials found improved FMD (flow-mediated dilation, an ultrasound test of artery relaxation) (Mohammadipoor 2022). FMD is an unvalidated surrogate, so no outcome benefit follows.

Cancer Prevention

Resveratrol blocked tumor stages in cell and mouse models (Jang 1997). Human data show only lower IGF-1 (insulin-like growth factor 1, a growth-promoting hormone) levels (Brown 2010); no outcome trials exist.

Benefit-Modifying Factors

  • Genetic variants: In the Alzheimer’s trial, the plasma Aβ40 (amyloid-beta 40, a plaque-forming protein fragment) effect appeared only in APOE4 carriers (the ε4 form of apolipoprotein E, a cholesterol-transport gene and major Alzheimer’s risk gene) (Turner 2015). No other gene-response data exist.
  • Baseline glycemia and weight: Glycemic benefits appear in diabetes but not in normal glucose tolerance, per a meta-analysis (Liu 2014); in another meta-analysis, systolic pressure reduction grew with baseline BMI (Fogacci 2019).
  • Baseline bone and cognitive status: Gains were larger in women with poorer bone-health markers (Wong 2020) and in those with lower baseline cognitive performance (Thaung Zaw 2020).
  • Sex: Bone gains appeared in postmenopausal women (Wong 2020) and obese men (Ornstrup 2014), yet nonobese postmenopausal women showed no metabolic effect (Yoshino 2012); obese-men trials split between positive (Timmers 2011) and null (Poulsen 2013). No head-to-head sex comparison exists.
  • Pre-existing conditions: An umbrella review across type 2 diabetes, metabolic syndrome, and fatty liver found mostly trivial effects, apart from short-term HbA1c falls in diabetes (Zeraattalab-Motlagh 2021); nonobese adults with normal glucose tolerance showed no effect (Yoshino 2012; Liu 2014).
  • Age: In aged men, resveratrol blunted training gains (Gliemann 2013), whereas adults aged 65–80 gained more strength with it (Alway 2017); older-adult evidence is otherwise sparse, per a systematic review (Yadegar 2024).

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: documented harms come from single trials, uncontrolled dose-escalation studies, or one cancer population, without replication in controlled trials from independent groups.

Medium 🟥 🟥

Blunted Adaptations to Exercise Training ⚠️ Conflicted

In aged men on eight weeks of intense training, 250 mg/day blunted gains in VO2max (maximal oxygen uptake, a strong predictor of longevity) and blocked training-related falls in blood pressure and LDL (Gliemann 2013, Copenhagen). In young men, 150 mg/day blunted peak-power gains from HIIT (high-intensity interval training) (Scribbans 2014, Ontario). Older adults on 500 mg/day gained more strength (Alway 2017), and pooled data show a non-significant impairment (Martinez-Negrin 2022). Net: blunting of aerobic adaptations is the more replicated signal.

Magnitude: VO2max rose 45% more with placebo than with resveratrol during training (Gliemann 2013); pooled effect on training adaptations SMD −0.54, not significant (95% CI −1.15 to 0.07; Martinez-Negrin 2022).

Low 🟥

Digestive Side Effects at Gram Doses ⚠️ Conflicted

Nausea and diarrhea occurred at 2.5–5 g/day (Brown 2010) and 2 g twice daily (la Porte 2010), both uncontrolled. In a 52-week RCT reaching 2 g/day, rates did not differ significantly from placebo (Turner 2015). Net: common only at gram doses.

Magnitude: Nausea or diarrhea in 42% on resveratrol versus 33% on placebo (p = 0.35; Turner 2015); diarrhea in 6 of 8 subjects at 4 g/day, no control group (la Porte 2010).

Liver Enzyme Elevation at High Doses ⚠️ Conflicted

At 3,000 mg/day for eight weeks, ALT and AST (aspartate aminotransferase, another liver enzyme) rose above placebo (Chachay 2014). At 1.5 g/day for six months, ALT did not differ from placebo (Heebøll 2016). Net: a high-dose signal only.

Magnitude: ALT and AST rose significantly more than with placebo through week 6 at 3,000 mg/day; the study reports this rise as statistically significant without an outcome figure (Chachay 2014); at 1.5 g/day ALT did not differ from placebo (p = 0.51; Heebøll 2016).

Unfavorable Cardiovascular Marker Shifts ⚠️ Conflicted

At 1,000 mg/day, LDL and total cholesterol rose versus placebo in men with metabolic syndrome (Kjær 2017), and a meta-analysis found lower HDL (high-density lipoprotein, a liver-bound cholesterol carrier) (Sahebkar 2015). A meta-analysis instead found lower LDL (Zhou 2022). Net: a gram-dose LDL rise is outweighed by pooled data.

Magnitude: HDL 4.18 mg/dL lower than control (95% CI −6.54 to −1.82; Sahebkar 2015); LDL rose significantly more than with placebo at 1,000 mg/day, and the abstract reports no outcome figure (Kjær 2017).

Acute Kidney Injury at Very High Doses ⚠️ Conflicted

A single-arm trial (no comparison group) of SRT501 at 5 g/day in myeloma was terminated after renal failures (Popat 2013; NCT00920556). A meta-analysis of 31 RCTs found no kidney harm at supplement doses (Hajhashemy 2025). Net: confined to that formulation and disease.

Magnitude: Serious acute renal failure in 3 and renal failure in 2 of 24 patients, no control group (NCT00920556).

Low Blood Cell Counts

At 1.5 g/day, one trial patient developed fever and bicytopenia (a fall in two blood cell types), reported as a serious adverse event (Heebøll 2016), and a case report describes resveratrol-induced thrombocytopenia (low platelet count) (Kumaran 2018). Both are isolated reports; causality is unconfirmed.

Magnitude: Not quantified in available studies. Only one trial adverse-event report and one case report exist, with no rates in a comparison group.

Speculative 🟨

Stimulation of Hormone-Sensitive Tissue

Resveratrol activated estrogen receptors and stimulated estrogen-dependent breast cancer cell growth in vitro (Gehm 1997). The basis is mechanistic only; no controlled human data exist.

Fetal Harm in Pregnancy

In pregnant rhesus monkeys, resveratrol enlarged the fetal pancreas by 42% with abnormal cell proliferation (Roberts 2014). The basis is animal data only; no human data exist.

Lower Adrenal Androgen Precursors

In middle-aged men, 1,000 mg/day lowered DHEA (dehydroepiandrosterone, an adrenal hormone precursor) and DHEAS (its sulfate) without changing testosterone (Kjaer 2015). These are unvalidated hormone markers; no clinical harm is documented.

Greater Brain Volume Loss in Alzheimer’s Disease

In the Alzheimer’s trial, brain volume declined more with resveratrol than placebo (Turner 2015). This is an unvalidated imaging marker whose meaning remains unresolved.

Risk-Modifying Factors

  • Genetic variants: People with reduced-function CYP2C9 variants who take warfarin could see compounded drug accumulation from resveratrol’s CYP2C9 inhibition (inferred; no human data). UGT1A1 (an enzyme that clears bilirubin and drugs) activity rose with resveratrol in people with low baseline activity (Chow 2010).
  • Baseline biomarkers: Pre-existing raised liver enzymes or reduced kidney function narrow the margin for the high-dose liver and kidney signals (Chachay 2014; NCT00920556).
  • Sex: Estrogen-receptor activity matters most for women with hormone-sensitive conditions (Gehm 1997) and in pregnancy (Roberts 2014); androgen-precursor reductions were documented in men (Kjaer 2015).
  • Pre-existing conditions: Multiple myeloma or kidney disease, bleeding disorders, hormone-sensitive cancers, and fatty liver disease at gram doses carry the documented or inferred risks above.
  • Age: Older adults more often take medicines cleared by CYP enzymes, which resveratrol inhibits (Chow 2010), raising interaction exposure (inferred); aged men showed blunted training adaptations (Gliemann 2013), although a systematic review of older-adult trials found no serious adverse events (Yadegar 2024).

Key Interactions & Contraindications

Documented interactions:

  • CYP3A4 substrates (drugs broken down by CYP3A4: carbamazepine, buspirone, simvastatin, tacrolimus): 500 mg/day for 10 days raised carbamazepine exposure (Bedada 2015); 1 g/day inhibited CYP3A4 activity (Chow 2010). Consequence: higher drug levels and toxicity for narrow-margin drugs; drug-level monitoring mitigates.
  • CYP2C9 substrates (diclofenac, celecoxib, ibuprofen, warfarin): diclofenac exposure doubled (Bedada 2016) and celecoxib exposure rose (Helal 2023); losartan metabolism fell (Chow 2010). Consequence: stronger NSAID (non-steroidal anti-inflammatory drug) or anticoagulant (anti-clotting) effects; INR (international normalized ratio, clotting-time test) checks for warfarin.
  • CYP2D6 substrates (dextromethorphan, metoprolol, tricyclic antidepressants (an older class of antidepressant medicines)): 1 g/day inhibited dextromethorphan metabolism (Chow 2010). Consequence: higher exposure and dose-related side effects such as dizziness or slowed heart rate; lower drug doses or monitoring mitigate.
  • CYP1A2 substrates (caffeine, theophylline, clozapine): 1 g/day induced caffeine metabolism (Chow 2010). Consequence: lower drug levels and reduced effect; drug-level monitoring for theophylline or clozapine.
  • CYP2E1 substrates (chlorzoxazone; CYP2E1 is a liver enzyme that also metabolizes alcohol): 500 mg/day for 10 days raised chlorzoxazone exposure (Bedada 2016). Consequence: stronger muscle-relaxant sedation; dose review mitigates.
  • Any regularly used medicine: EU-authorised trans-resveratrol supplements must state that people using medicines should consume them only under medical supervision (EU Implementing Decision 2016/1190). Consequence: unrecognized interactions; prescriber review mitigates.
  • High-fat meals: a high-fat breakfast cut resveratrol exposure by 45% versus a standard breakfast (la Porte 2010), while another study found a high-fat meal only delayed absorption (Vaz-da-Silva 2008). Consequence: lower exposure; dosing with a standard meal mitigates.
  • Quercetin and alcohol (no interaction found): quercetin 500 mg twice daily or 100 mL of 5% alcohol did not change resveratrol exposure (la Porte 2010).
  • Oral glucose-lowering drugs (metformin, sulfonylureas (drugs that make the pancreas release insulin) such as glipizide): adding 250 mg/day lowered HbA1c from baseline (Bhatt 2012); resveratrol metabolite levels tracked metformin dose (Timmers 2016). Consequence: hypoglycemia (abnormally low blood sugar); glucose monitoring after starting mitigates.
  • Piperine (no interaction found): piperine 5 or 25 mg taken with a single 2.5 g resveratrol dose did not significantly change resveratrol exposure in a randomized trial (Bailey 2021).

Theoretical interactions (inferred from mechanism, not studied in humans):

  • Anticoagulants and antiplatelet drugs (medicines that block clotting or platelet clumping: warfarin, apixaban, clopidogrel, aspirin): inferred from resveratrol’s antiplatelet activity in laboratory studies plus CYP2C9 inhibition. Consequence: increased bleeding risk; INR or bleeding-sign monitoring and stopping before surgery mitigate.
  • Supplements with additive antiplatelet effects (fish oil, ginkgo, vitamin E, garlic): inferred from shared platelet-inhibiting activity. Consequence: additive bleeding risk; avoiding high-dose combinations before procedures mitigates.
  • Insulin and glucose-lowering supplements (berberine): inferred from additive glucose lowering. Consequence: hypoglycemia; glucose monitoring after starting mitigates.
  • Blood-pressure-lowering drugs and supplements (amlodipine, lisinopril, magnesium, beetroot nitrate): inferred from additive blood-pressure lowering at 300 mg/day or more. Consequence: dizziness or low blood pressure; home blood-pressure checks mitigate.
  • Estrogen-modulating therapies (tamoxifen, anastrozole, menopausal hormone therapy): inferred from estrogen-receptor agonism. Consequence: possible interference with therapy effect; oncologist or prescriber review mitigates.

Populations who should avoid trans-Resveratrol:

  • Pregnancy and breastfeeding: inferred from fetal pancreatic enlargement in rhesus monkeys (Roberts 2014); no human data.
  • Children and adolescents (under 18 years): EU authorisation is restricted to the adult population (EU Implementing Decision 2016/1190).
  • Multiple myeloma or impaired kidney function, at gram doses (5 g/day studied): renal failure in 5 of 24 myeloma patients (NCT00920556); for existing kidney impairment this is inferred from those renal failures, with no data in that group.
  • Estrogen-sensitive cancers (breast, endometrial, ovarian): inferred from estrogen-receptor agonism and stimulation of estrogen-dependent breast cancer cells (Gehm 1997); no human data.
  • Bleeding disorders or upcoming surgery: inferred from antiplatelet activity and CYP2C9 inhibition; no human data.

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Dose ceiling of 1 g/day: Resveratrol is generally well tolerated up to 1 g/day, per a systematic review (Brown 2024), while digestive effects and liver-enzyme rises cluster at 2.5–3 g/day (Brown 2010; Chachay 2014); mitigates digestive and liver risks.
  • Medication review before starting: Checking for CYP3A4, CYP2C9, CYP2D6, and CYP1A2 substrates, with INR 1–2 weeks after starting for warfarin users, prevents unrecognized drug accumulation or loss of effect (Chow 2010).
  • Liver enzyme check: ALT and AST at baseline and 8–12 weeks at 1 g/day or more; stopping if ALT exceeds 3 times the upper limit of normal, a recognized liver-safety signal (Kullak-Ublick 2014), mitigates high-dose liver stress.
  • Kidney function and hydration: Creatinine at baseline at gram doses, and pausing during vomiting or diarrhea, mitigates dehydration-related kidney injury seen with very high doses (NCT00920556).
  • Training-block timing: Pausing resveratrol during blocks aimed at aerobic fitness gains, or taking it on rest days, mitigates blunted training adaptations (Gliemann 2013).
  • Pre-procedure pause: Stopping 1–2 weeks before surgery or dental extraction mitigates the inferred bleeding risk from antiplatelet activity.
  • Lipid recheck at high doses: A lipid panel 3 months after starting 1 g/day or more detects unfavorable HDL or LDL shifts seen in a meta-analysis and a trial (Sahebkar 2015; Kjær 2017).
  • Pregnancy exclusion: Stopping before attempting conception or at a positive pregnancy test prevents the fetal exposure flagged in primates (Roberts 2014).

Therapeutic Protocol

Each dose below is cited to its source; timing, splitting, and titration details without a citation reflect common practice.

  • Low-dose regimen (150 mg/day): 75 mg twice daily was used in the 12–24-month postmenopausal women’s trials (Wong 2020; Thaung Zaw 2020) and equals the EU maximum for supplements (EU Implementing Decision 2016/1190).
  • Moderate-dose regimen (150–500 mg/day): 150 mg/day was used in obese men (Timmers 2011) and 500 mg/day alongside exercise in adults aged 65–80 (Alway 2017).
  • High-dose regimen (1 g/day): Popularized by David Sinclair (Harvard; Sirtris co-founder), who takes 1 g each morning mixed into olive oil or yogurt (Huberman Lab episode with David Sinclair); 1 g/day was used in type 2 diabetes (Movahed 2013).
  • Non-use position: Peter Attia classifies resveratrol’s longevity case as lacking support (Attia, The Drive #300), and Andrew Huberman does not take it for lifespan (Huberman Lab AMA #12).
  • Time of day: Morning dosing gave higher bioavailability than later dosing (Almeida 2009), which also matches Sinclair’s practice.
  • Meal composition: A standard breakfast gave higher exposure than a high-fat breakfast (la Porte 2010), whereas Sinclair favors mixing it with fat; the two positions differ.
  • Half-life: Unchanged resveratrol has a half-life of 1–3 hours after one dose and 2–5 hours with repeated dosing (Almeida 2009); its metabolites have a half-life of about 9 hours (Walle 2004).
  • Single versus split dosing: Long-term trials split doses twice daily (Wong 2020); Sinclair takes one morning dose. The short half-life is the usual rationale for splitting.
  • Genetic polymorphisms: No pharmacogenetic dosing data exist; people with reduced-function CYP2C9 variants who take CYP2C9-cleared drugs are commonly kept at lower doses, inferred from resveratrol’s CYP2C9 inhibition (Chow 2010).
  • Sex: Positive female data come from 150 mg/day (Wong 2020); male trials used 150–1,000 mg/day (Ornstrup 2014). No sex-specific dosing comparison exists.
  • Age: In adults 65 and older, 1,000 mg/day raised cardiovascular risk markers while 300 mg/day did not (Mankowski 2020), supporting lower doses in older users.
  • Baseline biomarkers: People with raised HbA1c or fasting glucose respond more than those with normal glucose tolerance, per a meta-analysis (Liu 2014).
  • Pre-existing conditions: Type 2 diabetes trials added 250 mg–1 g/day to usual medicines (Bhatt 2012; Movahed 2013); gram doses are avoided in kidney disease (NCT00920556).

Discontinuation & Cycling

  • Intended duration: Longevity use is open-ended; Sinclair describes refining his daily protocol for about 10 years (Huberman Lab episode with David Sinclair), but the longest controlled trial lasted 24 months (Wong 2020).
  • Withdrawal effects: No withdrawal or rebound effects have been reported in human trials; benefits documented in trials are not shown to persist after stopping.
  • Tapering: No tapering protocol is needed or studied; resveratrol is stopped abruptly in trials without reported problems.
  • Cycling: No study shows that cycling preserves efficacy; pauses during aerobic training blocks are a common practice based on the blunting data (Gliemann 2013).
  • Stopping triggers: Persistent digestive upset, ALT above 3 times the upper limit of normal (Kullak-Ublick 2014), pregnancy, or planned surgery are common reasons to stop.

Sourcing and Quality

  • Isomer: trans-Resveratrol is the most abundant natural and most-researched form (ConsumerLab review); labels that state the trans- content and percentage allow dose comparison with trials.
  • Plant source: Most supplements derive from Japanese knotweed (Reynoutria japonica, syn. Polygonum cuspidatum) root (ConsumerLab review); lower-purity extracts can carry emodin, a laxative plant compound.
  • Synthetic and fermented forms: Synthetic trans-resveratrol (resVida, DSM) is the form authorised as an EU novel food (EU Implementing Decision 2016/1190); yeast-fermented Veri-te is another high-purity ingredient.
  • Purity and appearance: Sinclair advises discarding product that is not white or light gray, attributing diarrhea to brown, degraded, or contaminated material (Huberman Lab episode with David Sinclair); 98% or higher purity is the common benchmark.
  • Third-party testing: ConsumerLab tests label accuracy and contamination (ConsumerLab review); USP Verified (United States Pharmacopeia) or NSF Certified (NSF International) seals indicate independent verification.
  • Formulations: Micronized SRT501 was tied to kidney failures in myeloma (NCT00920556); absorption-enhanced formulations raise exposure substantially (Wang 2025), so trial doses may not transfer directly.
  • Storage: Light and air degrade resveratrol; Sinclair describes a lightproof bottle kept out of the air as stabilizing it (Huberman Lab episode with David Sinclair), and lightproof, sealed containers are standard.

Practical Considerations

  • Time to effect: Glycemic changes in diabetes appear within 4–12 weeks, per an umbrella review (Zeraattalab-Motlagh 2021); bone and cognitive changes were measured after 12 months (Wong 2020; Thaung Zaw 2020). Lifespan effects in humans have never been measured.
  • Common pitfalls: Relying on red wine (Sinclair estimates about 200 glasses for 1 g; Huberman Lab episode with David Sinclair), dosing with high-fat meals, buying unspecified isomer blends, and expecting training gains to grow.
  • Dietary intake: Resveratrol levels reached through a Western diet were not associated with mortality, inflammation, or cardiovascular disease in older adults (Semba 2014).
  • Regulatory status, US: Resveratrol is sold as a dietary supplement; manufacturers are responsible for safety and labeling before sale, and the FDA acts after products reach the market (FDA Dietary Supplements page).
  • Regulatory status, EU: trans-Resveratrol is an authorised novel food for adults only, in capsules or tablets, up to 150 mg/day, with a medical-supervision statement for people using medicines (EU Implementing Decision 2016/1190).
  • Cost and access: Resveratrol is widely available and not exceptionally expensive; cost rises mainly with gram-level doses and absorption-enhanced formulations.

Interaction with Foundational Habits

  • Sleep: None documented. No trial has measured sleep as an outcome, and none reports insomnia as a side effect; morning dosing, which gives higher bioavailability (Almeida 2009), also keeps intake away from bedtime.
  • Nutrition: Indirect. A standard meal gives higher exposure than a high-fat one (la Porte 2010); grapes, berries, and peanuts supply only milligram amounts; alcohol and quercetin do not change exposure (la Porte 2010).
  • Exercise: Blunting for aerobic training: 250 mg/day reduced VO2max and blood-pressure gains in aged men (Gliemann 2013), possibly by dampening the oxidative signals that drive adaptation; potentiating for strength in adults 65–80 (Alway 2017). Separating doses from aerobic blocks is common practice.
  • Stress management: Indirect, of unknown meaning. No human cortisol data exist; 1,000 mg/day lowered the adrenal hormones DHEA by 41% and DHEAS by 50% versus control in men (Kjaer 2015). No effect on mood was found in a meta-analysis of pooled trials (Khorshidi 2021).

Monitoring Protocol & Defining Success

Baseline testing: Before starting, a fasting blood panel records reference values for the markers trans-resveratrol is expected to change and for its safety signals: HbA1c and fasting glucose, a lipid panel, liver enzymes, creatinine, and resting blood pressure. People taking warfarin add an INR (international normalized ratio, a standardized clotting-time test).

Ongoing monitoring: Common practice repeats the panel at 8–12 weeks after starting or after any dose increase, then every 6–12 months while use continues; warfarin users recheck INR 1–2 weeks after starting. Liver enzymes and creatinine matter most at 1 g/day or more, where the liver-enzyme and kidney signals appeared. Success is defined by the individual’s goal: a falling HbA1c or blood pressure in those with elevated baseline values, stable safety markers, and unchanged training progress.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
HbA1c 4.0–5.6% (standard reference range) Expected to change: may fall in type 2 diabetes No fasting needed; pair with fasting glucose; no change expected with normal glucose tolerance (meta-analysis: Liu 2014)
Fasting glucose 70–99 mg/dL (standard reference range) Expected to change: falls in diabetes 8–12-hour fast; morning draw
Blood pressure Below 120/80 mmHg (“normal” category, ACC/AHA 2017 guideline) Expected to change: may fall at 300 mg/day or more ACC/AHA: American College of Cardiology/American Heart Association (Whelton 2018), whose clinician members earn revenue from diagnosing and treating high blood pressure, so lower thresholds widen their patient base; no separate laboratory reference range exists; seated, after 5 minutes’ rest, averaged readings
LDL and HDL cholesterol No established target; track change from own pre-supplement baseline Safety check: pooled trials lowered HDL, and 1 g/day raised LDL Fasting preferred; recheck at 3 months on 1 g/day or more (HDL fall in a meta-analysis: Sahebkar 2015; LDL rise at 1 g/day: Kjær 2017)
ALT and AST ALT 7–56 U/L, AST 10–40 U/L (standard reference range) Safety check: rise above 3 times upper limit stops use Above 3 times the upper limit is a liver-safety signal (Kullak-Ublick 2014); laboratory-specific limits; intense exercise in the prior 48 hours can raise AST; rises were seen at 3,000 mg/day (Chachay 2014)
Creatinine 0.7–1.3 mg/dL men, 0.6–1.1 mg/dL women (standard reference range) Safety check: rise signals kidney stress at gram doses Pair with eGFR (estimated glomerular filtration rate, a kidney-filtering estimate); hydrate normally (NCT00920556)
INR (warfarin users only) No established target for resveratrol; track against the prescriber’s target range Safety check: CYP2C9 inhibition can raise warfarin effect International normalized ratio; check 1–2 weeks after starting or changing dose (Chow 2010)

Qualitative markers:

  • Digestive tolerance (stool frequency, nausea, bloating), especially above 1 g/day
  • Training progress: aerobic capacity, interval power, and strength logs
  • Energy levels and general well-being
  • Subjective cognitive clarity and memory
  • Unusual bruising or bleeding, particularly with anticoagulants or antiplatelet supplements

Emerging Research

  • Resistance training in older adults (NCT06585865): Texas Tech trial in 36 adults aged 60+ testing 500 mg/day for 14 weeks with strength training; primary outcomes are muscle torque, strength, fatigability, and muscle mass, completion 2027. A positive result would support strength potentiation; a null or negative one would extend the blunting concern.
  • Estrogenic effects in postmenopausal women (NCT07865377): Randomized trial of 1,000 mg/day for 90 days in 80 women with coronary disease, measuring estradiol, estrone, SHBG (sex hormone-binding globulin, a sex-hormone carrier protein), and sirtuins 1 and 3; completion 2029. Rising estrogens would firm up the hormone-sensitive tissue risk; no change would weaken it.
  • Parkinson’s disease, enhanced formulation (NCT07592767): Georgetown phase 2a trial of JOTROL in 30 participants, assessing safety, tolerability, and plasma and cerebrospinal fluid levels; completion 2029. Good tolerability would support higher-exposure formulations; adverse events would reinforce the high-dose caution.
  • Inflammation in community-dwelling adults (NCT07395921): Trial in 75 adults of resveratrol-enriched grape-pomace bars, sponsored by a wine company’s research center, measuring CRP, IL-6 (interleukin-6, an inflammatory signal), and TNF-α; completion December 2026. A positive result would only modestly lift the inflammatory-marker item, given food form and sponsor; a null one would leave it unchanged.
  • Heart failure in postmenopausal women (NCT06828211): Open randomized trial of 500 mg/day knotweed-derived trans-resveratrol in 80 women with hypertension and low bone density; registered completion March 2025 has passed, and no results are posted.
  • Lifespan in mammals: Two Interventions Testing Program cohorts found no lifespan effect (Miller 2011; Strong 2013); an alternate-day dosing effect Sinclair describes in supplemental mouse data (Huberman Lab episode with David Sinclair) remains unreplicated.
  • Mechanism dispute: Whether supplement doses activate SIRT1 in human tissue remains open between assay-artifact critics (Pacholec 2010) and allosteric-activation evidence (Hubbard 2013); resolution would reshape the longevity rationale.
  • Exercise interaction: The only pooled estimate rests on two resveratrol trials (Martinez-Negrin 2022); larger trials separating aerobic from strength outcomes could confirm or remove the main risk for active adults.
  • Diabetes evidence update: The Cochrane review’s December 2018 search listed eight then-ongoing RCTs of about 800 participants (Jeyaraman 2020); no Cochrane update has appeared on PubMed since, so whether those trials resolve the glycemic conflict remains open.

Conclusion

trans-Resveratrol is a plant defense compound from grapes and Japanese knotweed that became one of the first popular longevity supplements after early studies in yeast, worms, and mice. For health-focused adults weighing it for longevity, the human evidence is narrower than that history suggests. The most consistent signal is a very small reduction in waist size. Single trials or one research group report slower loss of daily functioning in Alzheimer’s disease and less pain in women after menopause. Blood sugar improvements in people with type 2 diabetes appear in some trials but not in larger reviews that combine many trials, and in people with normal blood sugar, metabolic effects are largely absent. Effects on blood pressure, cholesterol, bone density, liver fat, kidney function, and memory are inconsistent, with combined analyses of many trials often showing no overall benefit. No human study shows longer life, and the animal lifespan gains did not hold in mice eating normal diets.

On the risk side, doses below about one gram a day are generally well tolerated, while gram-level doses bring digestive upset, liver enzyme rises, and, in one cancer population, kidney failure. Two findings matter particularly for active adults: resveratrol can weaken some fitness gains from endurance training, and it changes how the liver clears several common medicines.

The evidence base consists mostly of small, short trials, a disputed core mechanism, and research shaped in part by companies that developed or sold resveratrol products, which leaves its value for healthy, active adults uncertain.

Top - Benefits - Risks - Protocol